Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click here to learn how we are responding.
Traveling to Europe or Asia? Find a vaccine provider in your area.
Search Results
Please remember to call ahead to check for availability.

Showing 1 - 4 of Results

Please remember to call ahead to check for availability.
If you don't see a provider in your area, contact your PCP or nearest travel clinic to request the TicoVac® vaccine.
* Reported to have recently had TicoVac® in stock at particular pharmacy or clinic location.
This website is neither owned nor controlled by Pfizer. Pfizer does not endorse and is not responsible for the content or services of this site.

IMPORTANT SAFETY INFORMATION AND INDICATION

Important Safety Information
  • TicoVac® should not be given to anyone with a history of a severe allergic reaction after a previous dose of TicoVac.
  • TicoVac may not protect all individuals against TBE.
  • Some individuals with weakened immune systems may have a reduced immune response.
  • TicoVac contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases.
  • The most common adverse reactions in subjects 1 through 15 years of age who received TicoVac were local tenderness, local pain, headache, fever, and restlessness.
  • The most common adverse reactions in subjects 16 through 65 years of age who received TicoVac were local tenderness, local pain, fatigue, headache, and muscle pain.
  • Tell your healthcare provider if you are pregnant, or plan to become pregnant.
  • Ask your healthcare provider about the risks and benefits for TicoVac. Only a healthcare provider can decide if TicoVac is right for you.
Indication
  • TicoVac is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full prescribing information for TicoVac here.

IMPORTANT SAFETY INFORMATION AND INDICATION

Important Safety Information
  • TicoVac® should not be given to anyone with a history of a severe allergic reaction after a previous dose of TicoVac.
  • TicoVac may not protect all individuals against TBE.
  • Some individuals with weakened immune systems may have a reduced immune response.
  • TicoVac contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases.
  • The most common adverse reactions in subjects 1 through 15 years of age who received TicoVac were local tenderness, local pain, headache, fever, and restlessness.
  • The most common adverse reactions in subjects 16 through 65 years of age who received TicoVac were local tenderness, local pain, fatigue, headache, and muscle pain.
  • Tell your healthcare provider if you are pregnant, or plan to become pregnant.
  • Ask your healthcare provider about the risks and benefits for TicoVac. Only a healthcare provider can decide if TicoVac is right for you.
Indication
  • TicoVac is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full prescribing information for TicoVac here.

This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries.
The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.
  • © 2025 Pfizer Inc.
  • All rights reserved.
  • Pfizer Inc. PO Box 29387, Mission, KS 66201
  • November 2025
  • PP-TCV-USA-0218
  • PP-TCV-USA-0135
  • PP-TCV-USA-0219